Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Black Diamond Therapeutics to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.
Profitability
This table compares Black Diamond Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
| Black Diamond Therapeutics Competitors | -9,054.31% | -198.21% | -30.53% |
Insider & Institutional Ownership
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Black Diamond Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Diamond Therapeutics | $70.00 million | $22.37 million | -2.37 |
| Black Diamond Therapeutics Competitors | $737.75 million | $13.23 million | -10.05 |
Black Diamond Therapeutics’ competitors have higher revenue, but lower earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of current recommendations for Black Diamond Therapeutics and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 1 | 2 | 7 | 0 | 2.60 |
| Black Diamond Therapeutics Competitors | 9770 | 15029 | 45237 | 1570 | 2.54 |
Black Diamond Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 517.98%. As a group, “Biotechnology” companies have a potential upside of 95.42%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than its competitors.
Volatility and Risk
Black Diamond Therapeutics has a beta of 3.32, meaning that its stock price is 232% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics’ competitors have a beta of 1.07, meaning that their average stock price is 7% more volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats its competitors on 10 of the 13 factors compared.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
